San Diego based DexCom (NASDAQ:DXCM), a player in the self-monitoring of blood glucose (SMBG) business, designs and manufactures continuous glucose monitoring (CGM) systems for use by diabetes patients and healthcare providers in hospitals. The continuous glucose monitoring market in the United States is likely to grow at an impressive CAGR of around 14.2% during 2010-2015, reports RNCOS.
Self-monitoring of blood glucose is now playing an important role in the treatment of diabetes mellitus. With an increasing number of patients using SMBG devices, the market for SMBG devices is about $4.5 billion worth of sales, primarily spread among only three companies - Abbott (NYSE:ABT), Medtronic (NYSE:MDT) and DexCom. In this article I'll delve deeper
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|